Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
Transplant Cell Ther. 2024 Nov;30(11):1063.e1-1063.e19. doi: 10.1016/j.jtct.2024.07.004. Epub 2024 Jul 8.
Natural killer (NK) cells play a crucial role in the immune system's response against cancer. However, the challenge of obtaining the required quantity of NK cells for effective therapeutic response necessitates the development of strategies for their ex vivo expansion. This study aimed to develop a novel feeder cell line, K562.Clone1, capable of promoting the ex vivo expansion of NK cells while preserving their cytotoxic potential. he K562 leukemic cell line was transduced with mbIL-21 and 4-1BBL proteins to generate K562.Clone1 cells. NK cells were then co-cultured with these feeder cells, and their expansion rate was monitored over 14 days. The cytotoxic potential of the expanded NK cells was evaluated against acute myeloid leukemia blasts and tumor cell lines of leukemia and glial origin. Statistical analysis was performed to determine the significance of the results. The K562.Clone1 co-cultured with peripheral NK showed a significant increase in cell count, with an approximate 94-fold expansion over 14 days. Expanded NK cells demonstrated cytotoxicity against the tested tumor cell lines, indicating preservation of their cytotoxic characteristics. Additionally, the CD56, CD16, inhibitory KIRs, and activation receptors were conserved and present in a well-balanced manner. The study successfully developed a feeder cell line, K562.Clone1, that effectively promotes the expansion of NK cells ex vivo while maintaining their cytotoxic potential. This development could significantly contribute to the advancement of NK cell therapy, especially in Brazil.
自然杀伤 (NK) 细胞在免疫系统对抗癌症的反应中发挥着关键作用。然而,获得用于有效治疗反应所需数量的 NK 细胞的挑战需要开发其体外扩增的策略。本研究旨在开发一种新型饲养细胞系 K562.Clone1,能够在保持其细胞毒性潜力的同时促进 NK 细胞的体外扩增。将 mbIL-21 和 4-1BBL 蛋白转导到 K562 白血病细胞系中,生成 K562.Clone1 细胞。然后将 NK 细胞与这些饲养细胞共培养,并在 14 天内监测其扩增速度。通过对急性髓性白血病母细胞和白血病和神经胶质来源的肿瘤细胞系进行评估,评估了扩增的 NK 细胞的细胞毒性。进行了统计分析以确定结果的显著性。与外周 NK 共培养的 K562.Clone1 细胞计数显著增加,在 14 天内大约扩增了 94 倍。扩增的 NK 细胞对测试的肿瘤细胞系表现出细胞毒性,表明其细胞毒性特征得到了保留。此外,CD56、CD16、抑制性 KIR 和活化受体得到了保留,并以平衡的方式存在。该研究成功开发了一种饲养细胞系 K562.Clone1,可有效促进 NK 细胞的体外扩增,同时保持其细胞毒性潜力。这一发展可能会极大地促进 NK 细胞疗法的进展,特别是在巴西。